A review of the metabolic effects of sibutramine
Loading...
Date
Authors
Filippatos, T. D.
Kiortsis, D. N.
Liberopoulos, E. N.
Mikhailidis, D. P.
Elisaf, M. S.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Current Medical Research and Opinion
Book name
Book series
Book edition
Alternative title / Subtitle
Description
Background. Obesity is associated with an increased incidence of diabetes, hypertension, dyslipidaemia and coronary artery disease. Current management strategies of obesity include lifestyle interventions and pharmacotherapy. Sibutramine is a drug with established efficacy in weight reduction and maintenance of weight loss. It reduces food intake and attenuates the fall in metabolic rate associated with weight loss. Objective: To review the metabolic effects associated with sibutramine use. Methods: Relevant articles were identified through a Medline search (up to December 2004). Results: Weight loss with sibutramine treatment is associated with improved insulin sensitivity and a fall in glycosylated haemoglobin levels in type 2 diabetic patients. In most trials sibutramine exerted favourable effects on lipids, especially on high density lipoprotein (HDL) cholesterol and triglycerides, as well as on the total:HDL cholesterol ratio. Sibutramine also lowers serum uric acid concentrations. Furthermore, this drug seems to favourably influence adipocytokines; it reduces serum leptin and resistin levels and increases adiponectin levels. Sibutramine also exerts a beneficial effect on hyperandrogenaemia in obese women with polycystic ovary syndrome. Preliminary findings also suggest that weight loss following treatment with sibutramine is useful in patients with non-alcoholic fatty liver disease (NAFLD). Conclusion: Weight loss following sibutramine administration is associated with several favourable metabolic effects.
Description
Keywords
adipocytokines, cholesterol, high density lipoprotein cholesterol, insulin, lipids, sibutramine, type 2 diabetes, uric acid, weight loss, type-2 diabetes-mellitus, randomized controlled-trials, placebo-controlled trial, coronary-heart-disease, fatty liver-disease, serum uric-acid, weight-loss, obese-patients, double-blind, insulin-resistance
Subject classification
Citation
Link
<Go to ISI>://000228215500017
http://informahealthcare.com/doi/abs/10.1185/030079905X38132
http://informahealthcare.com/doi/abs/10.1185/030079905X38132
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής